• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Marijuana Stock Movers For July 19, 2024

    7/19/24 4:30:05 PM ET
    $CRBP
    $OGI
    $SOL
    $UGRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRBP alert in real time by email

    GAINERS:

    • Green Growth Brands (OTC:GGBXF) shares closed up 9900.00% at $0.0001
    • Rocky Mountain High (OTC:RMHB) shares closed up 33.33% at $0.02
    • SOL Glb Inv (OTC:SOLCF) shares closed up 19.57% at $0.05
    • Affinor Growers (OTC:RSSFF) shares closed up 19.12% at $0.08
    • Pharmadrug (OTC:LMLLF) shares closed up 18.52% at $0.02
    • 1933 Industries (OTC:TGIFF) shares closed up 8.23% at $0.01
    • Cansortium (OTC:CNTMF) shares closed up 7.14% at $0.15
    • CV Sciences (OTC:CVSI) shares closed up 7.12% at $0.06
    • CLS Holdings USA (OTC:CLSH) shares closed up 6.26% at $0.04
    • Cipher Pharmaceuticals (OTC:CPHRF) shares closed up 5.67% at $6.43
    • Body and Mind (OTC:BMMJ) shares closed up 5.40% at $0.03
    • OrganiGram Holdings (NASDAQ:OGI) shares closed up 4.93% at $1.65
    • Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 3.71% at $58.00
    • Emeren Group (NYSE:SOL) shares closed up 3.28% at $1.83

    LOSERS:

    • Global Hemp Group (OTC:GBHPF) shares closed down 63.20% at $0.02
    • Elixinol Wellness (OTC:ELLXF) shares closed down 51.61% at $0.00
    • Maple Leaf Green World (OTC:MGWFF) shares closed down 47.96% at $0.02
    • Global Compliance (OTC:FUAPF) shares closed down 31.67% at $0.00
    • CNBX Pharmaceuticals (OTC:CNBX) shares closed down 17.14% at $0.01
    • Leafbuyer Techs (OTC:LBUY) shares closed down 16.67% at $0.0005
    • Kaya Holdings (OTC:KAYS) shares closed down 12.53% at $0.04
    • RIV Capital (OTC:CNPOF) shares closed down 11.76% at $0.09
    • C21 Investments (OTC:CXXIF) shares closed down 11.00% at $0.24
    • Blueberries Medical (OTC:BBRRF) shares closed down 9.09% at $0.01
    • Urban-gro (NASDAQ:UGRO) shares closed down 7.19% at $1.49
    • iAnthus Capital Hldgs (OTC:ITHUF) shares closed down 5.59% at $0.02
    • Target Group (OTC:CBDY) shares closed down 5.56% at $0.00
    • Cresco Labs (OTC:CRLBF) shares closed down 5.49% at $1.64
    • Green Thumb Industries (OTC:GTBIF) shares closed down 4.94% at $11.15
    • Curaleaf Holdings (OTC:CURLF) shares closed down 3.26% at $4.15
    • cbdMD (AMEX:YCBD) shares closed down 3.19% at $0.60

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CRBP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRBP
    $OGI
    $SOL
    $UGRO

    CompanyDatePrice TargetRatingAnalyst
    Organigram Global Inc.
    $OGI
    1/27/2026Buy
    Canaccord Genuity
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    12/2/2024Overweight
    Piper Sandler
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2024$85.00Outperform
    Wedbush
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/22/2024$80.00Buy
    H.C. Wainwright
    Organigram Global Inc.
    $OGI
    7/17/2024Speculative Buy
    Canaccord Genuity
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    6/26/2024$85.00Buy
    B. Riley Securities
    More analyst ratings

    $CRBP
    $OGI
    $SOL
    $UGRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Smethurst Dominic sold $26,575 worth of shares (3,285 units at $8.09), decreasing direct ownership by 3% to 95,887 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:25:42 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian sold $19,537 worth of shares (2,415 units at $8.09), decreasing direct ownership by 4% to 51,927 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:24:39 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian was granted 28,365 shares, increasing direct ownership by 109% to 54,342 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    1/16/26 4:30:03 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    $OGI
    $SOL
    $UGRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Organigram Global

    Canaccord Genuity initiated coverage of Organigram Global with a rating of Buy

    1/27/26 9:29:20 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Corbus Pharma

    William Blair initiated coverage of Corbus Pharma with a rating of Outperform

    2/28/25 7:22:12 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    $OGI
    $SOL
    $UGRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organigram Reports First Quarter Fiscal 2026 Results

    Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2

    2/10/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report First Quarter Fiscal 2026 Results on February 10, 2026

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 10, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

    2/3/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum

    CHARLOTTE, N.C., Feb. 2, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), a leading innovator in wellness and hemp-derived consumer products, today announced a major distribution expansion for its Herbal Oasis THC-infused social seltzer ("Oasis") through an expanded partnership with Morales Beverage Group ("MBG"). The agreement extends Oasis into Louisiana, strengthening the brand's regional footprint across the Gulf South and creating a more contiguous platform for continued Southeast growth, following strong early performance in Texas. With MBG's established statewide distribut

    2/2/26 9:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $CRBP
    $OGI
    $SOL
    $UGRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN Shah Capital Management bought $29,786 worth of American Depositary Shares (16,853 units at $1.77) (SEC Form 4)

    4 - Emeren Group Ltd (0001417892) (Issuer)

    12/20/24 4:05:29 PM ET
    $SOL
    Semiconductors
    Technology

    CHAIRMAN Shah Capital Management bought $104,290 worth of American Depositary Shares (58,921 units at $1.77) (SEC Form 4)

    4 - Emeren Group Ltd (0001417892) (Issuer)

    12/16/24 6:39:51 AM ET
    $SOL
    Semiconductors
    Technology

    Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    9/24/24 4:04:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    $OGI
    $SOL
    $UGRO
    SEC Filings

    View All

    SEC Form 10-Q filed by urban-gro Inc.

    10-Q - urban-gro, Inc. (0001706524) (Filer)

    2/10/26 3:34:03 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    2/10/26 1:14:49 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    2/10/26 7:41:44 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    $OGI
    $SOL
    $UGRO
    Leadership Updates

    Live Leadership Updates

    View All

    Organigram Announces Appointment of Chief Executive Officer

    Organigram Global Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company's new Chief Executive Officer (CEO). Mr. Yamanaka is expected to assume the role effective on or about January 15, 2026. Mr. Yamanaka will also join the Company's board of directors when he assumes the role of Chief Executive Officer. Mr. Yamanaka is a seasoned executive, having spent more than 20 years at British American Tobacco, with extensive experience in strategy and general management across

    11/25/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emeren Group Announces North America Management Change and Preliminary Q2 2025 Operating Results

    NORWALK, Conn., July 3, 2025 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE:SOL), a leading global solar project developer, owner, and operator, today announced a leadership transition within its North America operations. Mr. Cameron "Mac" Moore, Executive Vice President - North America, has departed the Company, and Mr. M. Jahangir Alam has been appointed as his successor, effective immediately. About M. Jahangir Alam M. Jahangir Alam is a seasoned leader in the North American renewable energy industry, with nearly three decades of experie

    7/3/25 4:30:00 PM ET
    $SOL
    Semiconductors
    Technology

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    $OGI
    $SOL
    $UGRO
    Financials

    Live finance-specific insights

    View All

    Organigram Reports First Quarter Fiscal 2026 Results

    Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2

    2/10/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report First Quarter Fiscal 2026 Results on February 10, 2026

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 10, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

    2/3/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

    CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with hemp derived THC beverage line Herbal Oasis today announced our financial results for the full fiscal year ended September 30, 2025. For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science. The Company

    12/19/25 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $CRBP
    $OGI
    $SOL
    $UGRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    $OGI
    $SOL
    $UGRO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary